Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD to present at JonesResearch Radiopharma Day

Wednesday, October 2, 2024 1 min read
Key Takeaway: Radiopharm Theranostics (RADX) is set to present at the upcoming JonesResearch Radiopharma Day. This presentation follows several positive clinical updates and the initiation of a Phase 1/2a clinical study for their product BetaBart (RV-01). The company has also received IND approval from the FDA to target B7H3 with this therapeutic study.

Market Sentiment Analysis

POSITIVE FACTORS

  • RAD is actively participating in industry events.
  • The company is making progress in clinical studies.
  • Positive updates across multiple programs indicate growth.

Full Press Release Details

• Announcements
• October 2, 2024
Loading Viewer…

More Announcements & Updates

• Updates
• January 24, 2025
• Announcements
• January 25, 2022
• Announcements
• September 30, 2024
• Announcements
• October 29, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the purpose of RAD's presentation?

RAD's presentation aims to showcase their advancements in clinical studies.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a product undergoing Phase 1/2a clinical studies by RAD.

When is the JonesResearch Radiopharma Day?

The specific date for the JonesResearch Radiopharma Day was not mentioned.

What recent approvals has RAD received?

RAD received IND approval from the FDA for their therapeutic study targeting B7H3.

Tags: RADX Viatris Investor Conferences Healthcare JonesResearch Radiopharma Day BetaBart clinical study
Last updated: Oct 2, 2024